OREXIGEN PRESENTS CONTRAVE CLINICAL REVIEW AT CBI.
Orexigen Therapeutics, Inc. (NASDAQ: OREX), a biopharmaceutical
company focused on the treatment of central nervous system (CNS)
disorders including obesity, presented at The Center for . . .
CYTRX CLINICAL TRIAL OF ARIMOCLOMOL FOR ALS SHOWS
PROMISE.
CytRx Corporation (NASDAQ:CYTR), Los Angeles, Calif., a
biopharmaceutical company engaged in the development and
commercialization of human therapeutics, has announced promising data
from the . . .
AFFYMETRIX COMPLETES LARGEST GENECHIP PLANT MICROARRAY
STUDY.
The Virginia Bioinformatics Institute (VBI) at Virginia Tech,
Blacksburg,Va., has completed the largest ever Affymetrix GeneChip(r)
microarray study for a plant experimental system in an academic . . .
ROYALTY PHARMA/INNEXUS SIGN PACT FOR DXL ANTIBODY.
Royalty Pharma and InNexus Biotechnology Inc. (BULLETIN BOARD:
IXSBF) have announced that Royalty Pharma would purchase a royalty
interest in up to two products targeting cancer based on . . .
HEMISPHERX/ARMADA TO LAUNCH ALFERON N INJECTION.
Hemispherx Biopharma, Inc. (AMEX: HEB) has entered into an
agreement with Armada Health Care to launch their natural interferon,
Alferon N Injection(r) (Alferon(r)), FDA approved for HPV . . .
ANTISENSE AGENT PROMISING TREATMENT FOR HEART DISEASE.
Animal studies of a potentially breakthrough medical technology
that uses a novel antisense agent to arrest the process of coronary
arteries becoming reblocked after treatment with angioplasty . . .
FDA APPROVES XYZAL TABLETS FOR THE RELIEF OF
ALLERGIES/HIVES.
UCB and sanofi-aventis have announced that the U.S. Food and Drug
Administration (FDA) has approved XYZAL(R) (levocetirizine
dihydrochloride), a new once-daily prescription antihistamine . . .
ATHELON HEMOPURIFIER REMOVES MORE THAN 99% OF DENGUE
VIRUS.
Aethlon Medical, Inc. (OTCBB:AEMD), San Diego, has announced that
researchers at the National Institute of Virology (NIV) in India have
documented that the Aethlon Hemopurifier(R) is highly . . .
ARTHROCARE GETS FDA CLEARANCE FOR ALL-PEEK IMPLANT
SYSTEM.
ArthroCare Corp.(Nasdaq:ARTC), Austin, Texas, has received 510(k)
clearance from the U.S. Food and Drug Administration to market its
Magnum PI Knotless Implant System, which utilizes implants made . . .
ANTIOXIDANT MOLECULE MINIMIZES STROKE-LINKED BRAIN
DAMAGE.
A novel peptide discovered by researchers at Weill Cornell Medical
College could prove a potent weapon against stroke, a new study finds.
The compound, called SS31, is able to cross the . . .
SEVERE TRAUMA AFFECTS CHILD'S BRAIN FUNCTION.
The first study to examine brain activity patterns in severely
traumatized children showed their brains function differently than those
of healthy children, say researchers at the Stanford . . .
GLAXOSMITHKLINE FILES ROTARIX APPLICATION FOR FDA
APPROVAL.
AVANT Immunotherapeutics (Nasdaq: AVAN), Needham, Mass, has
announced that its partner, GlaxoSmithKline (GSK) Biologicals, has filed
a marketing application for the Rotarix vaccine with the United . . .
CELLDEX THERAPEUTICS INITIATES PHASE 2/3 TRIAL OF CDX110.
Celldex Therapeutics, Phillipsburg, N.J, has announced that the
company has initiated the ACT III study, a randomized, multi-institution
Phase 2/3 clinical trial. The study will investigate the . . .
BAXTER UNVEILS HYLENEX FOR OPHTHALMIC SURGERY.
Baxter Healthcare Corporation, San Diego, Calif., has unveiled
HYLENEX recombinant (hyaluronidase human injection) for the
ophthalmology market for use in enhancing the absorption and dispersion
of . . .
BIDIL HAS SHOWN REDUCTIONS IN DEATH OF BLACK HEART
PATIENTS.
A study comparing the formulations of isosorbide dinitrate (ISDN)
and hydralazine (HYD) used in V-HeFT I and V-HeFT II, and BiDil, the
proprietary fixed dose combination, used in the African . . .
TARGACEPT INITIATES PHASE I CLINICAL TRIAL OF TC-5619.
Targacept, Inc. (NASDAQ: TRGT), Winston-Salem, N.C., a
clinical-stage biopharmaceutical company developing a new class of drugs
known as NNR Therapeutics(TM), has initiated a Phase I clinical trial . . .
EXUBERA SHOWED PULMONARY SAFETY WITH BLOOD SUGAR CONTROL.
Results from three-year interim analyses of two ongoing long- term
clinical trials showed that small mean declines in lung function in
diabetes patients who took Exubera (insulin human [rDNA . . .
NEURONASCENT LICENSES ANIMAL CELLS TO LIFELINE CELL
TECHNOLGY.
Neuronascent, Inc., Clarksville, Md., has announced that the
license of animal cells to Lifeline Cell Technology, LLC, a wholly owned
subsidiary of International Stem Cell Corporation. The . . .
AVICENA FILES COMPOSITION OF MATTER PATENT APPLICATION.
Avicena Group, Inc. (BULLETIN BOARD: AVGOE), Palo Alto, Calif., a
late stage biotechnology company focused on commercializing its
proprietary cellular energy modulation technology, has filed . . .
MEDIMMUNE STARTS PHASE I TRIAL FOR PSORIASIS TREATMENT.
Medarex, Inc. (NASDAQ: MEDX), Princeton, N.J., has announced that
its partner MedImmune, Inc. has initiated a Phase I clinical trial of
MEDI-545 for the potential treatment of psoriasis. MEDI-545 . . .
|
|